Antitumor activity of AMG 102 in combination with bevacizumab or motesanib. Antitumor activity of AMG 102 in combination with bevacizumab or motesanib.

Slides:

Advertisements

Similar presentations

CS-1 Results of the Phase 3 Clinical Trials of Abraxane vs. Taxol in Metastatic Breast Cancer William J. Gradishar, MD, FACP Professor of Medicine Northwestern.

Advertisements

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

P.A. Tang 1, S. J. Cohen 1, G. Bjarnason 1, C. Kollmannsberger 1, K. Virik 1, M. J. MacKenzie 1, J. Brown 1, L. Wang 1, A. Chen 2, M. J. Moore 1 1 Princess.

KEYNOTE-021: Pembrolizumab + Ipilimumab Active in Previously Treated Advanced NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

CCO Independent Conference Coverage

Gajria D et al. Proc SABCS 2010;Abstract P

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.

Figure 1. MORT gene silencing is early event in cancer

Dose-escalation patient response.

سرطان الثدي Breast Cancer

Patient disposition for the double-blind study period.

Breast cancer. Breast cancer. A, antitumor activity of abemaciclib in a human xenograft model (T47D) of ER-positive, HER2-negative breast cancer. Athymic.

NSCLC. NSCLC. A, antitumor activity of abemaciclib in 4 KRAS-mutant (NCI-H358, NCI-H2122, NCI-H441, NCI-H460) and 2 KRAS wild-type (WT; NCI-H1650, NCI-H1975)

Baselga J et al. SABCS 2009;Abstract 45.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Waterfall plots of the best per cent change from baseline in sum of longest diameters (SLD) for target lesions. Waterfall plots of the best per cent change.

Clinical courses of patients.

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Distribution of informative SNPs with LOH (black bars) on each chromosome (rows, oriented p-arm at the bottom and q-arm at the top of each chromosome)

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Antitumor activity of bevacizumab in PDX models was not correlated with the ratio of human and mouse VEGF-A of the models. Antitumor activity of bevacizumab.

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma per health-insurance (NHIF) status at diagnosis (P=0.003). Kaplan-Meier.

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

Three-year DFS rates of T x N subsets of the ACTS-CC trial and IDEA study.19 Annotation: definitions of DFS in ACTS-CC and IDEA were different. Three-year.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Frequent alterations identified and potential actionability.

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

A and B, images from a patient with an invasive carcinoma on the floor of the mouth. A and B, images from a patient with an invasive carcinoma on the floor.

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

IL-13Rα2 expression is associated to human colon cancer progression and poor survival of patients with colorectal cancer. IL-13Rα2 expression is associated.

Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.

EN1 expression in breast cancer and clinical outcome.

ALDH1A3 expression levels are inversely correlated with the survival of patients with resectable mass-forming and advanced cholangiocarcinoma, respectively.

A, unsupervised clustering of all BRCA1 (red), BRCA2 (blue), and sporadic (green) breast tumors of our collection using the regions reported as discriminative.

Mir-128 reduction in breast cancer tissues correlates chemotherapy resistance and poor patient survival. Mir-128 reduction in breast cancer tissues correlates.

Duration of treatment and intervals of radiographic and ctDNA response

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer (patient 6). Gamma camera images at 72 h of patient with T4N2M1 ductal breast cancer.

Establishment of 12 PDX from BRAF inhibitor–progressed patients.

Example inverse FF-OCT images (left column) and corresponding histology images (right column) of ovarian metastases. Example inverse FF-OCT images (left.

Antitumor activity. Antitumor activity. A, maximum change in target lesion size from baseline assessed according to RECIST 1.0 (n = 26). Six patients had.

PSMA expression in pre- and posttreatment prostate carcinoma serum.

Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.

Mean cell number in small intestinal crypt (a), small intestinal villus (b), and midcolonic crypt (c) of BALB/c (♦) and DBA/2 (▪) mice after two injections.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Influence of ASGR2 expression on survival.

Location of the ER mutations and frequencies per cohort.

Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.

Frequent coamplification of RTKs in MET-amplified EGC

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.

MGA271 mediates in vitro ADCC across a panel of ATCC cancer cell lines exhibiting a range of B7-H3 expression. MGA271 mediates in vitro ADCC across a panel.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

DFS and DSS curves according to low, intermediate, and high stromal CD8+ T-cell density in the four different cohorts; A and B, University Hospital of.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

Genetic analysis suggests the presence of four clinically relevant groups of histologically defined anaplastic oligodendrogliomas. Genetic analysis suggests.

A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.

Patient stratification using survival risk prediction and BCLC staging

Progression and survival analysis.

Survival, subsequent therapies, and response.

STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C.

Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots.

Presentation transcript:

Antitumor activity of AMG 102 in combination with bevacizumab or motesanib. Antitumor activity of AMG 102 in combination with bevacizumab or motesanib. A, best result of 10 evaluable patients according to modified RECIST (bars). Four patients (breast cancer, colon cancer, bladder cancer, and unknown carcinoma) discontinued before postdose tumor assessment as a result of disease progression, adverse events, or serious adverse events. B, progression-free survival and diagnosis for 10 evaluable patients according to modified RECIST. Each bar is labeled by cohort number (1 = 3 mg/kg AMG 102 plus 10 mg/kg bevacizumab; 2 = 10 mg/kg AMG 102 plus 10 mg/kg bevacizumab; 3 = 20 mg/kg AMG 102 plus 10 mg/kg bevacizumab; 4 = 3 mg/kg AMG 102 plus 75 mg/day motesanib). *, patient had best response of progressive disease owing to the development of new lesions; all other patients had best response of stable disease. †, patients without progressive disease at the last disease assessment date were censored. Peter J. Rosen et al. Clin Cancer Res 2010;16:2677-2687 ©2010 by American Association for Cancer Research